A recent phase 3 trial, EV-302, demonstrated that the combination of enfortumab vedotin and pembrolizumab significantly improves survival rates compared to standard platinum-based chemotherapy in patients with advanced urothelial cancer.
Survival Rates Increase with Combination Therapy
The EV-302 study revealed that patients receiving enfortumab vedotin plus pembrolizumab experienced longer progression-free and overall survival than those treated with traditional platinum-based chemotherapy protocols.
Patients Experience Better Quality of Life
Beyond survival benefits, individuals on the combination therapy reported lower pain levels and enhanced overall health status, indicating a superior quality of life during treatment.
- Combination regimen emerges as a preferred first-line treatment for advanced urothelial cancer.
- Enhanced pain management observed in patients with significant baseline discomfort.
- Supports integrating patient-reported outcomes in future cancer treatment assessments.
The findings advocate for the adoption of enfortumab vedotin and pembrolizumab as frontline therapy, offering patients not only extended survival but also improved comfort and well-being during their cancer treatment journey.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
